Recurrent Nasopharyngeal Carcinoma Clinical Trial
Official title:
A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC
This phase II trial studies how well durvalumab and epacadostat work in treating patients with Epstein-Barr virus positive nasopharyngeal cancer that cannot be removed by surgery (unresectable), has come back (recurrent), or has spread to other places in the body (metastatic). Epacadostat blocks the enzyme, IDO1, from working. Blocking this enzyme may allow for a stronger immune response against cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving durvalumab and epacadostat may work better in treating patients with nasopharyngeal cancer compared to durvalumab alone.
PRIMARY OBJECTIVE: I. Determine whether adding an IDO inhibitor to PD-L1 antibody therapy improves the probability of remission in nasopharyngeal carcinoma (NPC). SECONDARY OBJECTIVES: I. Determine whether adding an IDO inhibitor to PD-L1 antibody therapy improves long-term clinical outcomes in NPC. II. Determine whether the combination of durvalumab and epacadostat in recurrent and metastatic NPC patients is safe and well tolerated. EXPLORATORY OBJECTIVES: I. Identify potential associations between pre-treatment and on-treatment regulatory and effector immune cell populations and clinical outcomes in NPC patients treated with durvalumab and epacadostat. II. Characterize the oral and fecal microbiome in responding and non-responding patients. OUTLINE: Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study. After completion of study treatment, patients are followed up every 3 months until start of a new anti-cancer treatment, until 30 days after documented disease progression, until death, or until 36 months from the initiation of treatment on study, whichever comes first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06010095 -
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03639467 -
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06029270 -
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03666221 -
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05350891 -
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
|
Phase 2 | |
| Active, not recruiting |
NCT04586088 -
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
|
Phase 2 | |
| Active, not recruiting |
NCT04405622 -
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
|
Phase 2 | |
| Recruiting |
NCT06235203 -
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
|
Phase 3 | |
| Not yet recruiting |
NCT04215510 -
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
|
Phase 3 | |
| Recruiting |
NCT03930498 -
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03907826 -
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
|
Phase 3 | |
| Recruiting |
NCT04376866 -
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
|
Phase 3 | |
| Not yet recruiting |
NCT05432219 -
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
|
N/A | |
| Recruiting |
NCT04425265 -
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
|
N/A | |
| Not yet recruiting |
NCT03689556 -
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
|
||
| Not yet recruiting |
NCT03210389 -
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
|
Phase 2 | |
| Completed |
NCT01370070 -
MK-2206 in Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT01392235 -
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
|
Phase 2 | |
| Not yet recruiting |
NCT06228079 -
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
|
Phase 3 | |
| Terminated |
NCT04458909 -
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 3 |